Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5586737 | 0.81 | HPGD (0.50) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL1415318 | 0.81 | P2RX7 (0.45) | GABRA1GABRB2TSHRCA2LMNA | |
| SCHEMBL30566931 | 0.81 | P2RX7 (0.45) | GABRA1GABRB2TSHRCA2LMNA | |
| SCHEMBL633569 | 0.80 | GABRA1 (0.65) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL7677412 | 0.80 | GABRA1 (0.65) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL7675674 | 0.80 | GABRA1 (0.65) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL15485453 | 0.79 | GABRA1 (1.00) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL51565 | 0.79 | GABRA1 (0.71) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL43297 | 0.79 | GABRA1 (1.00) | GABRA1GABRB2TSHRPOLBCA2 | |
| SCHEMBL11611313 | 0.79 | GABRA1 (0.56) | GABRA1GABRB2TSHRPOLBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | INHERIS BIOPHARMA INC (US) | 2020-03-12 | — | — | US | disclosed |
| CN-105503889-B | Oligomer-opioid agonist conjugates | 尼克塔治疗公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-10143690-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180296550-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | NEKTAR THERAPEUTICS | 2018-10-18 | — | — | US | disclosed |
| US-20180256563-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2018-09-13 | — | — | US | disclosed |
| US-9925182-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound | NEKTAR THERAPEUTICS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2456469-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | Nektar Therapeutics (US) | 2012-05-30 | — | — | EP | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2011011543-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-6127371-A | FOR TREATMENT OR PREVENTION OF CARDIOVASCULAR AND RENAL DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5985886-A | USEFUL IN THE TREATMENT OF A VARIETY OF CARDIOVASCULAR AND RENAL DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5942516-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1999-08-24 | — | — | US | disclosed |
| EP-0854721-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0854721-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10143690-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-20180256563-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-20180296550-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | OPRL1, OPRM1, OPRK1 | GABRA1 232/4885GABRB2 458/4885TSHR 1448/4885 |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | GABRA1 248/4885GABRB2 470/4885TSHR 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.